Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $2.5 million.

  • TransMedics' Change in Account Payables rose 691944.44% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 15064.87%. This contributed to the annual value of -$1.4 million for FY2024, which is 12006.61% down from last year.
  • Per TransMedics' latest filing, its Change in Account Payables stood at $2.5 million for Q3 2025, which was up 691944.44% from -$1.2 million recorded in Q2 2025.
  • TransMedics' 5-year Change in Account Payables high stood at $3.9 million for Q4 2021, and its period low was -$4.0 million during Q1 2022.
  • In the last 5 years, TransMedics' Change in Account Payables had a median value of $416000.0 in 2023 and averaged $496105.3.
  • Its Change in Account Payables has fluctuated over the past 5 years, first plummeted by 479390.24% in 2022, then skyrocketed by 691944.44% in 2025.
  • Quarter analysis of 5 years shows TransMedics' Change in Account Payables stood at $3.9 million in 2021, then crashed by 93.17% to $264000.0 in 2022, then soared by 57.58% to $416000.0 in 2023, then crashed by 854.33% to -$3.1 million in 2024, then skyrocketed by 178.23% to $2.5 million in 2025.
  • Its Change in Account Payables was $2.5 million in Q3 2025, compared to -$1.2 million in Q2 2025 and $781000.0 in Q1 2025.